ReviewBiomedicines2025
The Gut Microbiome in Human Obesity: A Comprehensive Review.
Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Trial
- Abdominal Bloating in the Modern Era: Pathophysiological Mechanisms and Environmental Contributors.Biomolecules · 2026Review
- Dietary Matcha Attenuates High-Fat High-Sugar Diet-Induced Cardiomyocyte Hypertrophy in Association with Gut Microbiota Remodeling in Mice.Nutrients · 2026Article
- Bifidobacterium breve BBr60 Improves Metabolic Abnormalities by Regulating Gut Microbiota Balance in a High-Fat Diet-Induced Obese Mouse Model.Diabetes, obesity & metabolism · 2026Article
- A Randomized Controlled Trial to Evaluate the Effects of Full-Fat and Low-Fat Fermented Dairy Foods on Markers of Cardiometabolic Health in Adults with Overweight or Obesity and Elevated Fasting Triglycerides.Current developments in nutrition · 2026Article
- Associations Between Microbial Depletion and Autonomic Dysregulation in Binge-Eating Disorder.The International journal of eating disorders · 2026Article
- Beyond One-Size-Fits-All: Individually Tailored Dietary Interventions in Modern Obesity Care.Nutrients · 2026Review
- Sulforaphane and Broccoli-Derived Preparations in Obesity and Obesity-Related Metabolic Dysfunction: Mechanistic Insights, Preclinical Evidence, and Clinical Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Gut Microbiota in Metabolic Syndrome: Differences in Microbial Signatures and Clinical Profiles.Medicina (Kaunas, Lithuania) · 2026Review
- Nordic Walking Combined with Time-Restricted Eating Is Associated with Changes in Gut Microbiota Composition in Adults with Obesity-Pilot Study.Nutrients · 2026Article
- Reframing obesity through the gut microbiota: functional dysbiosis and metabolic disease.Current opinion in clinical nutrition and metabolic care · 2026Review
- Strain-Specific Effects of three Different Native Lactobacillus on Anthropometric Indices, Appetite, and Nesfatin-1 in Obese Adults: A Triple-Blind Randomized Clinical Trial.Probiotics and antimicrobial proteins · 2026Article
- Plant-Derived Foods and Medicines as Modulators of the Gut Microbiome: Molecular Interactions and Implications for Disease and Therapy.Molecules (Basel, Switzerland) · 2026Review
- Gut Microbiome-Hormone Interactions and Precision Fermentation in the Prevention of Early Cardiovascular Risk in Adolescents.International journal of molecular sciences · 2026Review
- Nervonic Acid Prevents HFD-Induced Metabolic Dysfunction and Is Associated with Gut Microbiota Remodeling.Metabolites · 2026Article
- Microbiomics: Novel Biomarkers of Colorectal Cancer Diagnosis and Prognosis.Diagnostics (Basel, Switzerland) · 2026Review
- Multi-Omics Analyses of the Gut Microbiota and Metabolism in Cats with Different Body Conditions and the Effects of Fecal Microbiota Transplantation.Veterinary sciences · 2026Article
- Review of the Use of Digital Therapeutics for Obesity Treatment: Toward a Psychological Phenotyping.Advances in nutrition (Bethesda, Md.) · 2026Review
- Review
- Propolis in Obesity and Related Metabolic Disorders: Mechanistic and Clinical Insights-A Scoping Review.Nutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An estimated 2.6 billion individuals are currently living with overweight or obesity, and this number is projected to exceed 4 billion by 2035. Consequently, unless this increasing trajectory is effectively addressed, the trend is expected to continue in the coming years. The gut microbiome has emerged as a central regulator of host metabolism and energy homeostasis, making its detailed characterization crucial for the advancement of innovative therapeutic strategies and for elucidating mechanisms underlying metabolic health and disease. This review examines human obesity through the lens of the gut microbiome, providing a comprehensive overview of its role by addressing gut microbiome alterations, microbiome-driven mechanisms, dietary influences, prebiotic effects, microbiome-based therapeutics, and other approaches in the treatment of obesity and related metabolic disorders. The composition of the gut microbiome is altered in obesity and characterized by reduced microbial diversity and inconsistent shifts in dominant bacterial phyla, which collectively contribute to metabolic dysregulation. The gut microbiome influences obesity through multiple mechanisms. These include regulating energy balance and insulin sensitivity via short-chain fatty acids, inducing chronic inflammation, modulating metabolic and appetite genes, altering bile acid signaling, and promoting fat storage by inhibiting fasting-induced adipose factor. Dietary patterns exert a profound influence on gut microbiome composition and function, with plant-based diets conferring protective effects against obesity and its comorbidities. Microbiome-based therapeutics, including probiotics, synbiotics, and fecal microbiota transplantation, have demonstrated potential in modulating key metabolic and inflammatory pathways associated with obesity. As the scientific understanding of the human gut microbiome continues to advance, the integration of microbiome-based therapies into standard clinical practice is poised to become increasingly feasible and therapeutically transformative, particularly for obesity, a complex condition that demands innovative and customized interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.